Fleming & Company, Pharmaceuticals
Jump to navigation
Jump to search
Fleming & Company, Pharamceuticals, Inc. of Fenton, Missouri, was founded in 1960 by Tom E. Fleming.
ThyroShield
ThyroShield™ Potassium Iodide Oral Solution received U.S. Food and Drug Administration approval January 12, 2005.
- "Approval of the liquid KI as a pediatric formulation was given last year by the Interagency Weapons of Mass Destruction Medical Countermeasures Subcommittee. Children are the most susceptible to the dangerous effects of radioactive iodine.
- "Once it is delivered to HHS, the pediatric KI will be made available to states that submit and receive approval from HHS for plans they develop to distribute the new product in communities around commercial nuclear power plants.
- "The Food and Drug Administration (FDA) has approved KI in tablet form as a nonprescription drug for use as a 'blocking agent' to prevent the human thyroid gland from absorbing radioactive iodine. On Jan. 12, 2005, the FDA granted approval to Fleming for their product ThyroShieldTM (Potassium Iodide Oral Solution, USP) 65 mg/ml for children." [1]
- See ThyroShield and Press Release posted January 24, 2005, on ThyroShield.com website.
ThyroShield is readily available OTC (over the counter) online.
Contact Details
1733 Gilsinn Lane
Fenton (St. Louis County), Missouri 63026
Tel: 636-343-5306
Fax: 636-343-5322
URL: http://www.flemingcompany.com
SourceWatch Resources
External links
- Press Release: "HHS Awards Bioshield Contract for Liquid Potassium Iodide," HHS, March 18, 2005.
- "HHS Awards Bioshield Contract for Liquid Potassium Iodide," Medical News Today, March 19, 2005: $5.7 million contract "for the manufacture and delivery of 1.7 million pediatric doses of liquid potassium iodide (KI)."
